Gateway for:

Member Countries

Early Diagnostics of Alzheimer’s Disease


Studies on the Enzymatic Protein Synthesis in Order to Create the Amplification Method for Beta-Amyloid Useful in the Laboratory Diagnostics of Alzheimer’s Disease

Tech Area / Field

  • MED-DID/Diagnostics & Devices/Medicine
  • BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology
  • BIO-CHM/Biochemistry/Biotechnology

3 Approved without Funding

Registration date

Leading Institute
Institute of Gerontology, Russia, Moscow

Supporting institutes

  • Institute of Cell Biophysics, Russia, Moscow reg., Puschino\nState Research Center for Applied Microbiology, Russia, Moscow reg., Obolensk\nInstitute of Bioorganic Chemistry (Branch), Russia, Moscow reg., Puschino


  • Vanderbilt University / Department of Pharmacology, USA, TN, Nashville\nNational Institute of Environmental Health Sciences, USA, NC, Research Triangle Park\nDuke University / Medical Center / Department of Pharmacology and Cancer Biology, USA, NH, Durham

Project summary

Alzheimer’s disease is a very dangerous neurodegenerative illness. It’s characterized by a long period of incubation and by the lack of any symptoms and early diagnostic tests. Pharmacotherapy was unsuccessful hitherto. Post-mortem histological and electron microscopic studies on brain sections of patients indicated the presence of specific beta-amyloid protein structures.

The main objectives of the project are the study on enzymatic protein synthesis in cell-free system, to create reaction for beta-amyloid protein amplification and a standard sensitive system for the enzymatic protein synthesis allowing maximal accumulation of beta-amyloid. The laboratorial diagnostics for early stages of Alzheimer’s disease would be elaborated on the basis of the protein amplification.

The specific objectives of the project can be summarized as follows:

1. To study concentration, temperature, and time dependences in cell-free system for enzymatic protein synthesis.

2. To create and develop the standard system for beta-amyloid protein amplification in a test sample and to study the effects of some key reagents on the beta-amyloid protein synthesis.

3. To study the parameters of commercial beta-amyloid formation in the standard test-system for protein amplification, and to develop incubation conditions allowing to accumulate beta-amyloid in microamount sufficient for its further identification.

4. To develop the method for identification of beta-amyloid in the standard test-system.

5. To create the animal model of Alzheimer’s disease in mice and to expand the new method for identification of beta-amyloid in animal tissues.

6. To evolve the methodology of preparing biomaterials from animals and humans for the beta-amyloid protein amplification. To carry out preclinic work-up using the method of early identification of beta-amyloid.

7. To device early laboratory diagnostics of Alzheimer’s disease and early identification of beta-amiloid, and to carry out the clinical investigation.

Project participants are qualified scientists in knowledge-intensive technologies and animal using and modeling human diseases, possess methods for cell-free protein synthesis, protein isolation and fractionation, protein identification from solutions and biological samples, pre-clinic and clinic investigations.